Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

FDA approves sNDA for Sunovion's Aptiom

October 20, 2017 12:28 AM UTC

FDA approved an sNDA for Aptiom eslicarbazepine acetate (BIA 2-093, SEP-0002093) from the Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) to treat partial-onset seizures in patients age ≥4. Aptiom is already approved for the indication in adults...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article